Codon Devices and Blue Heron reach settlement.Cambridge, MA and Bothell, WA 3/31/08 -- Synthetic biology Synthetic biology has long been used to describe an approach to biology that attempts to integrate different areas of research in order to create a more holistic understanding of life. firm Codon codon: see nucleic acid. Devices and Blue Heron Biotechnology, a provider of gene synthesis services, have settled their legal dispute stemming from Codon's 2007 suit against Blue Heron. The suit alleged infringement of four patents owned by Duke University (US Patent Nos. 5,459,039; 5,556,750; 5,679,522; and 5,702,894) and one MIT MIT - Massachusetts Institute of Technology patent (US Patent No. 5,750,335), covering gene assembly and nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. preparation and manufacturing. The patents are exclusively licensed to Codon. Under the settlement agreement, Codon granted Blue Heron a perpetual and fully paid sublicense to error correction technology. Financial terms were not disclosed. Codon Devices and Blue Heron are two competitors in the rapidly growing large-scale gene synthesis market. The market is estimated at $50 million annually, according to The New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of Times. On March 31, Codon also announced it had added $11 million to its Series B round of financing, bringing the total to $31 million. |
|
|||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion